Elite Journal of Medical Sciences. Volume 2 issue 1 (2024), Pp. 44-52
https://epjournals.com/journals/EJMS

Effects of Long-Term Omeprazole Use on Red Blood Cells: A Review

Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

E-mail: emmanuelobeagu@yahoo.com, obeagu.emmanuel@kiu.ac.ug, 0000-0002-4538-0161

Abstract

Omeprazole, a proton pump inhibitor (PPI), stands as a cornerstone in managing acid-related disorders like gastroesophageal reflux disease (GERD) and peptic ulcers. However, the widespread use of omeprazole has raised concerns regarding its potential impact on various physiological systems, including hematological parameters, particularly red blood cells (RBCs). This comprehensive review aims to synthesize existing literature, delving into the effects of long-term omeprazole use on RBCs, elucidating underlying mechanisms, clinical implications, and avenues for further investigation. Omeprazole's primary mode of action involves inhibiting the H+/K+-ATPase proton pump, effectively reducing gastric acid secretion. Emerging evidence suggests a plausible association between prolonged omeprazole use and alterations in RBC parameters. This review scrutinizes the impact on RBCs, examining changes in hemoglobin levels, hematocrit, mean corpuscular volume (MCV), and red blood cell counts, and delves into the potential mechanisms driving these hematological alterations. The consequences of omeprazole-induced hypochlorhydria on essential nutrient absorption necessary for RBC production and function are under scrutiny. The clinical implications of these observed alterations in RBC parameters secondary to long-term omeprazole use remain a subject of debate. In conclusion, while evidence suggests potential hematological effects of long-term omeprazole use on RBC parameters, further exploration is essential to establish causal relationships and determine clinical relevance. Clarifying these effects will significantly contribute to refining clinical practices, guiding appropriate patient management, and enhancing the safety profile of prolonged omeprazole therapy.

Keywords*: Omeprazole, proton pump inhibitor, red blood cells, anemia*

Introduction

Citation: Obeagu EI. Effects of Long-Term Omeprazole Use on Red Blood Cells: A Review. Elite Journal of Medica Science, 2024; 2(1): 44-52

Omeprazole, a proton pump inhibitor (PPI), has revolutionized the management of acid-related gastrointestinal disorders, becoming one of the most widely prescribed medications globally. Its efficacy in reducing gastric acid secretion by inhibiting the H+/K+-ATPase proton pump has made it a cornerstone in the treatment of conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related ailments. However, alongside its therapeutic benefits, concerns have emerged regarding potential unintended effects, particularly on hematological parameters, notably red blood cells (RBCs).[1] While primarily recognized for its role in gastric acid suppression, recent investigations have shed light on the intricate relationship between long-term omeprazole use and alterations in RBC parameters. The implications of these changes in hematological indices, including hemoglobin levels, hematocrit, mean corpuscular volume (MCV), and red blood cell counts, have prompted a reexamination of omeprazole's broader systemic impact.[2]

This paper aims to delve into the effects of prolonged omeprazole use specifically on RBCs, scrutinizing the emerging body of evidence, exploring potential mechanisms underlying hematological alterations, assessing clinical implications, and identifying avenues for further exploration. Understanding the potential impact of omeprazole on RBCs is of paramount importance, considering the central role of red blood cells in oxygen transport, tissue perfusion, and overall physiological homeostasis. The mechanisms proposed to underlie omeprazole's potential effects on RBC parameters encompass disruptions in iron absorption, alterations in gut microbiota impacting nutrient absorption, potential interference with vitamin B12 metabolism, and direct impacts on erythropoiesis. These mechanisms raise pertinent questions regarding the broader implications of omeprazole-induced hypochlorhydria and its potential consequences on essential nutrient uptake critical for RBC production and function.[3] Amidst these considerations, the clinical significance and risks associated with alterations in RBC parameters due to prolonged omeprazole use remain areas of ongoing exploration and debate. Clarifying these effects is imperative to inform clinical practice, guide appropriate patient management, and ensure optimal therapeutic outcomes while mitigating potential hematological repercussions.[4]

Omeprazole

Omeprazole is a proton pump inhibitor (PPI) widely used in the management of various acid-related gastrointestinal disorders. It exerts its therapeutic effects by selectively inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cells, thereby reducing the secretion of gastric acid into the stomach.[5] Omeprazole irreversibly binds to the proton pump (H+/K+-ATPase) in the stomach's parietal cells. By inhibiting this enzyme, it blocks the final step in gastric acid secretion, leading to a profound reduction in the production of gastric acid.[6] Omeprazole is available in different formulations, including capsules, tablets, and oral suspension. It is also available as an over-the-counter (OTC) medication at lower strengths for short-term use.[7] Common side effects of omeprazole can include headache, nausea, diarrhea, and abdominal pain. Long-term use may be associated with potential risks such as an increased susceptibility to certain infections, vitamin and mineral deficiencies (e.g., magnesium, vitamin B12), and potential bone fractures, especially in elderly individuals.[8] Omeprazole can interact with various medications, altering their effectiveness or increasing the risk of side effects. For instance, it can affect the absorption of

certain drugs (e.g., antifungals, anticoagulants) that require an acidic environment for optimal absorption.[9] Omeprazole is typically recommended for short-term use, but in certain conditions requiring long-term acid suppression, physicians may prescribe it for extended periods. Regular monitoring and assessment are essential for individuals on prolonged therapy.[10] Omeprazole should be used cautiously in specific populations, including pregnant or breastfeeding individuals and those with certain medical conditions, such as liver disease or hypersensitivity to PPIs. As with any medication, it's crucial to take omeprazole as prescribed by a healthcare professional, ensuring adherence to dosage recommendations and being aware of potential risks and side effects, especially with long-term use. Regular follow-ups and discussions with a healthcare provider are essential for monitoring and managing any potential concerns associated with omeprazole therapy.

Red blood cells

Red blood cells (RBCs), also known as erythrocytes, are specialized cells that play a vital role in the human body's oxygen transport system. They are the most abundant cells in the blood and are responsible for carrying oxygen from the lungs to tissues throughout the body and transporting carbon dioxide back to the lungs for exhalation.[11] Mature RBCs are biconcave disc-shaped cells without a nucleus, enabling flexibility and increased surface area for efficient gas exchange. Their unique structure allows them to pass easily through narrow capillaries.1[2] Red blood cells contain hemoglobin, a protein that binds to oxygen in the lungs and releases it to tissues throughout the body. Hemoglobin also helps in carrying carbon dioxide back to the lungs.[13] RBCs are produced in the bone marrow through a process called erythropoiesis, which is regulated by the hormone erythropoietin, primarily secreted by the kidneys in response to low oxygen levels.[14] The average lifespan of a red blood cell is approximately 120 days. After this period, aged or damaged RBCs are removed from circulation and broken down in the spleen and liver.[15] The primary function of RBCs is to transport oxygen to body tissues and remove carbon dioxide. Their ability to bind and release oxygen is crucial for cellular respiration, providing oxygen to organs and tissues for energy production.[16] The proportion of red blood cells in the total blood volume is known as hematocrit. It is commonly used as a measure of RBC concentration in the blood and is expressed as a percentage of total blood volume. Maintaining the proper number and function of red blood cells is critical for overall health. Abnormalities in RBC count, size, or function can lead to various conditions, such as anemia (a decrease in the number of RBCs or hemoglobin), which can result in fatigue, weakness, and decreased oxygen delivery to tissues. Regular blood tests, such as complete blood count (CBC), can provide information about RBC count, hemoglobin levels, and other related parameters, helping in the diagnosis and management of conditions affecting red blood cells.

Impact on Red Blood Cells

The impact of certain medications, like omeprazole, on red blood cells (RBCs) has been a topic of interest due to potential associations between long-term use and alterations in hematological parameters. While omeprazole primarily targets gastric acid secretion, emerging evidence suggests its possible influence on RBC indices, although the direct mechanisms remain under investigation.[17] Omeprazole-induced hypochlorhydria (reduced stomach acid) might affect iron

absorption. Impaired acid production could hinder the release of iron from food, potentially leading to decreased iron availability for RBC production. This can contribute to decreased hemoglobin synthesis and possibly result in microcytic anemia.[18] Long-term omeprazole use has been associated with decreased absorption of vitamin B12, essential for normal RBC production and maturation. Reduced vitamin B12 availability might impair erythropoiesis and result in megaloblastic anemia or other hematological abnormalities.[19] Prolonged omeprazole use has been linked to hypomagnesemia (low magnesium levels), which might indirectly affect RBC function. Magnesium plays a role in maintaining cell membrane stability and electrolyte balance within cells, potentially impacting RBC integrity and function.[20] Potential impacts on other nutrients crucial for erythropoiesis, such as folic acid, might also be influenced by long-term omeprazole use, although direct evidence linking omeprazole to folic acid deficiency and subsequent effects on RBCs remains less established.[21] While these potential impacts are under scrutiny, it's important to note that the clinical significance of alterations in RBC indices due to omeprazole use is still a subject of ongoing research. Not all individuals on omeprazole therapy will experience significant changes in their hematological parameters. Healthcare providers prescribing omeprazole or similar medications often consider the risks and benefits, especially in cases of long-term use. Monitoring RBC indices, particularly in individuals on prolonged omeprazole therapy, may be recommended to assess for any hematological abnormalities. Additionally, supplementation or dietary adjustments might be considered to mitigate potential deficiencies affecting RBC production and function.

Mechanisms and Pathophysiological Considerations

The potential impact of omeprazole on red blood cells (RBCs) involves various mechanisms and pathophysiological considerations that warrant exploration to understand the observed alterations in hematological parameters associated with prolonged omeprazole use. Omeprazole, by inhibiting gastric acid secretion, creates a hypochlorhydric environment in the stomach. Reduced acidity may impair the solubilization of dietary iron, leading to decreased absorption. This disruption in iron absorption might limit iron availability for erythropoiesis, potentially affecting hemoglobin synthesis and contributing to microcytic anemia.[22] Long-term omeprazole use has been linked to decreased absorption of vitamin B12. Vitamin B12 is vital for DNA synthesis and maturation of RBCs. Deficiency in vitamin B12 could result in ineffective erythropoiesis, leading to macrocytic anemia or other hematological abnormalities.[23] Omeprazole use might impact gut microbiota composition, potentially affecting nutrient absorption. Disruptions in the gut microbiome can hinder the absorption of essential nutrients necessary for RBC production, indirectly influencing hematological parameters.[24] While evidence is less definitive, prolonged use of omeprazole might influence folate absorption or metabolism. Folate is essential for DNA synthesis and cell division, including RBC production. Deficiency in folate could contribute to megaloblastic anemia or other hematological changes.[25] Omeprazole has been associated with hypomagnesemia, which might impact cellular function, including RBCs. Magnesium plays a role in maintaining cell membrane stability and intracellular processes, and its deficiency could potentially affect RBC integrity and function.[26] The impact of omeprazole on hematological parameters involves complex interactions and might not be solely attributed to a single mechanism. Other factors, such as individual

variability in response to omeprazole, concomitant medication use, diet, and underlying health conditions, might contribute to observed hematological changes.[27] Understanding these mechanisms and pathophysiological considerations is crucial for clinicians to monitor and manage potential hematological alterations in individuals on long-term omeprazole therapy. Regular assessment of hematological parameters and consideration of potential nutrient deficiencies associated with omeprazole use can aid in mitigating the risk of adverse effects on red blood cells and overall hematopoiesis.

Clinical Implications and Risks

The clinical implications and potential risks associated with alterations in red blood cells (RBCs) due to long-term omeprazole use are essential considerations for healthcare providers managing individuals on prolonged therapy. While the precise clinical significance remains a subject of ongoing investigation, there are potential implications and risks that warrant attention: Prolonged omeprazole use, particularly in susceptible individuals, might lead to various forms of anemia, including microcytic or macrocytic anemia. Changes in RBC indices, such as reduced hemoglobin levels or altered mean corpuscular volume (MCV), could indicate potential hematological abnormalities requiring clinical assessment.[28] Omeprazole-induced hypochlorhydria may impair iron absorption, potentially leading to iron deficiency. Clinically, this could manifest as iron-deficiency anemia, characterized by low hemoglobin and ferritin levels, impacting RBC production and oxygen-carrying capacity.[29] Decreased vitamin B12 absorption associated with long-term omeprazole use might lead to vitamin B12 deficiency. This deficiency could result in megaloblastic anemia or neurological complications, affecting RBC maturation and overall hematopoiesis.[30] Omeprazole's influence on gastric acidity might impact the absorption of other nutrients crucial for erythropoiesis, such as folate and magnesium. Deficiencies in these nutrients could affect RBC production and cellular function, potentially leading to anemia or other hematological disturbances.[31] Healthcare providers managing patients on prolonged omeprazole therapy should consider monitoring RBC indices, hemoglobin levels, and related parameters periodically. Assessing for signs of anemia or hematological abnormalities, especially in at-risk individuals, is crucial for timely intervention and management. Not all individuals on long-term omeprazole therapy will experience significant hematological changes. Factors such as age, nutritional status, concurrent medications, and underlying health conditions can influence an individual's susceptibility to hematological alterations due to omeprazole use. Clinicians must weigh the potential risks of hematological alterations against the benefits of omeprazole therapy in managing acid-related disorders. Individualized assessment and monitoring can help balance the therapeutic advantages of omeprazole with potential hematological risks.While omeprazole's impact on RBCs and hematological parameters remains an area of ongoing research, healthcare providers should be vigilant in monitoring for potential hematological abnormalities in individuals on prolonged omeprazole therapy. Timely assessment, addressing nutrient deficiencies, and individualized management strategies are essential in mitigating potential risks and ensuring optimal patient care.

Future Directions and Recommendations

Future research directions and recommendations regarding the impact of long-term omeprazole use on red blood cells (RBCs) and hematological parameters can pave the way for a deeper understanding of this relationship. To advance knowledge in this area, several avenues for research and clinical practice merit consideration: Conducting in-depth mechanistic studies to elucidate the precise pathways through which omeprazole influences RBC parameters. This includes investigating the effects on iron metabolism, vitamin B12 absorption, folate metabolism, and other essential nutrients critical for erythropoiesis. Designing longitudinal studies to assess the long-term impact of omeprazole therapy on RBC indices and hematological parameters. Tracking changes in RBC parameters over extended periods in a diverse patient population can provide valuable insights into potential trends, risks, and clinical significance.[32] Initiating well-designed clinical trials to evaluate the clinical significance of alterations in RBC indices due to omeprazole use. Randomized controlled trials assessing hematological outcomes in individuals on prolonged omeprazole therapy compared to control groups can help establish causal relationships and assess the associated risks. Conducting population-based studies to determine the prevalence and incidence of hematological abnormalities associated with omeprazole use across different demographic groups. This includes exploring susceptibility factors, such as age, gender, comorbidities, and nutritional status. Developing and recommending optimized monitoring strategies for healthcare providers managing patients on long-term omeprazole therapy. Establishing guidelines for routine monitoring of RBC parameters and implementing protocols for early detection and management of potential hematological abnormalities. Investigating the efficacy of nutritional interventions or supplementation strategies to mitigate potential deficiencies induced by omeprazole therapy. Assessing the impact of targeted supplementation on preventing or ameliorating hematological alterations associated with omeprazole use. Updating and refining clinical guidelines to incorporate evidence-based recommendations for monitoring and managing hematological parameters in individuals on prolonged omeprazole therapy. This includes providing guidance on screening, assessment, and intervention strategies tailored to different patient populations. Implementing educational initiatives for healthcare professionals and patients to increase awareness about potential hematological risks associated with long-term omeprazole use. Promoting informed decision-making and proactive monitoring to ensure optimal patient outcomes. Focusing on comprehensive research endeavors, incorporating robust clinical studies, optimizing monitoring strategies, and updating clinical guidelines can contribute significantly to advancing knowledge and refining clinical practices concerning the impact of omeprazole on RBCs and hematological parameters. Such efforts are essential for enhancing patient care, minimizing potential risks, and optimizing therapeutic outcomes in individuals on prolonged omeprazole therapy.

Conclusion

The relationship between long-term omeprazole uses and its potential impact on red blood cells (RBCs) and hematological parameters represents a complex and evolving area of investigation within the realm of pharmacology and clinical practice. While omeprazole stands as an effective medication for managing acid-related gastrointestinal disorders, concerns have surfaced regarding its potential influence on essential factors affecting RBC production and function. Healthcare

providers should maintain vigilance in monitoring hematological parameters in patients on prolonged omeprazole therapy, especially in those predisposed to nutritional deficiencies or hematological abnormalities. Individualized assessments, periodic monitoring, and proactive management strategies are essential to ensure optimal patient outcomes while navigating the potential hematological implications of long-term omeprazole use.

In essence, while acknowledging the complexities and uncertainties surrounding the impact of omeprazole on RBCs, continued research, informed clinical practices, and patient-centered approaches will be instrumental in advancing our understanding and refining management strategies for individuals receiving prolonged omeprazole therapy. These endeavors aim to strike a balance between therapeutic efficacy and minimizing potential hematological risks, thereby optimizing the safety and efficacy of omeprazole treatment in clinical practice.

References

1. Scarpignato, C., Gatta, L., Zullo, A., Blandizzi, C., SIF-AIGO-FIMMG Group Carmelo Scarpignato Corrado Blandizzi Luigi Gatta Angelo Zullo Anna Kohn Gioacchino Leandro Antonio Balzano Alberto Chiriatti Walter Marocco and Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners, 2016. Effective and safe proton pump inhibitor therapy in acid-related diseases–a position paper addressing benefits and potential harms of acid suppression. *BMC medicine*, 14: 1-35.
2. Losurdo G, Caccavo NL, Indellicati G, Celiberto F, Ierardi E, Barone M, Di Leo A. Effect of Long-Term Proton Pump Inhibitor Use on Blood Vitamins and Minerals: A Primary Care Setting Study. Journal of Clinical Medicine. 2023;12(8):2910.
3. Gröber U, Schmidt J, Kisters K. Important drug-micronutrient interactions: A selection for clinical practice. Critical reviews in food science and nutrition. 2020;60(2):257-75.
4. Bell V, Rodrigues AR, Antoniadou M, Peponis M, Varzakas T, Fernandes T. An Update on Drug–Nutrient Interactions and Dental Decay in Older Adults. Nutrients. 2023;15(23):4900.
5. Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. International journal of clinical practice. 2005;59(6):709-15.
6. Sakai H, Fujii T, Takeguchi N. Proton-potassium (H+/K+) ATPases: Properties and roles in health and diseases. The Alkali Metal Ions: Their Role for Life. 2016:459-83.
7. Ronchi F, Sereno A, Paide M, Sacré P, Guillaume G, Stéphenne V, Goole J, Amighi K. Development and evaluation of an omeprazole-based delayed-release liquid oral dosage form. International Journal of Pharmaceutics. 2019; 567:118416.
8. Al Ali HS, Jabbar AS, Neamah NF, Ibrahim NK. Long-Term Use of Omeprazole: Effect on Haematological and Biochemical Parameters. Acta Med Indones. 2022;54(4):585-94.
9. Li W, Zeng S, Yu LS, Zhou Q. Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Therapeutics and Clinical Risk Management. 2013:259-71.

Citation: Obeagu EI. Effects of Long-Term Omeprazole Use on Red Blood Cells: A Review. Elite Journal of Medica Science, 2024; 2(1): 44-52

10. Raghunath AS, O'morain C, McLoughlin RC. the long-term use of proton-pump inhibitors. Alimentary pharmacology & therapeutics. 2005; 22:55-63.
11. Jensen FB. The dual roles of red blood cells in tissue oxygen delivery: oxygen carriers and regulators of local blood flow. Journal of Experimental Biology. 2009;212(21):3387-93.
12. Lima AC, Alvarez-Lorenzo C, Mano JF. Design advances in particulate systems for biomedical applications. Advanced Healthcare Materials. 2016;5(14):1687-723.
13. Glenn A, Armstrong CE. Physiology of red and white blood cells. Anaesthesia & Intensive Care Medicine. 2019;20(3):170-4.
14. Jelkmann W. Erythropoietin. Sports Endocrinology. 2016; 47:115-27.
15. Corrons JV, Casafont LB, Frasnedo EF. Concise review: how do red blood cells born, live, and die? Annals of hematology. 2021 Oct;100(10):2425-33.
16. Jensen FB. The dual roles of red blood cells in tissue oxygen delivery: oxygen carriers and regulators of local blood flow. Journal of Experimental Biology. 2009;212(21):3387-93.
17. Al Ali HS, Jabbar AS, Neamah NF, Ibrahim NK. Long-Term Use of Omeprazole: Effect on Haematological and Biochemical Parameters. Acta Med Indones. 2022;54(4):585-94.
18. Kaczmarczyk O, Przybylska-Feluś M, Piątek-Guziewicz A, Wcisło K, Krośniak M, Kryczyk-Kozioł J, Kleszcz K, Zagrodzki P, Cibor D, Mach T, Zwolińska-Wcisło M. Effect of long-term proton pump inhibitor therapy on complete blood count parameters and selected trace elements: a pilot study. Polskie Archiwum Medycyny Wewnętrznej= Polish Archives of Internal Medicine. 2020;130(3).
19. Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapies. 2021;76(1):13-21.
20. Chandra A, Rawat B, Chokhani R. Proton Pump Inhibitor Induced Hypokalemia. J Clin Cas e Stu. 2017;2(5):2.
21. Sobczyńska-Malefora A, Delvin E, McCaddon A, Ahmadi KR, Harrington DJ. Vitamin B12 status in health and disease: a critical review. Diagnosis of deficiency and insufficiency–clinical and laboratory pitfalls. Critical reviews in clinical laboratory sciences. 2021;58(6):399-429.
22. Schubert ML. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Current opinion in gastroenterology. 2017;33(6):430-8.
23. Sobczyńska-Malefora A, Delvin E, McCaddon A, Ahmadi KR, Harrington DJ. Vitamin B12 status in health and disease: a critical review. Diagnosis of deficiency and insufficiency–clinical and laboratory pitfalls. Critical reviews in clinical laboratory sciences. 2021;58(6):399-429.
24. Singh A, Cresci GA, Kirby DF. Proton pump inhibitors: risks and rewards and emerging consequences to the gut microbiome. Nutrition in Clinical Practice. 2018;33(5):614-24.
25. Hughes CF, Ward M, Hoey L, McNulty H. Vitamin B12 and ageing: current issues and interaction with folate. Annals of clinical biochemistry. 2013;50(4):315-29.
26. Humphrey ML, Barkhordari N, Kaakeh Y. Effects of omeprazole on vitamin and mineral absorption and metabolism. Journal of Pharmacy Technology. 2012;28(6):243-8.
27. Wiciński M, Węclewicz MM, Miętkiewicz M, Malinowski B, Grześk E, Klonowska J. Potential mechanisms of hematological adverse drug reactions in patients receiving

clozapine in combination with proton pump inhibitors. Journal of Psychiatric Practice. 2017;23(2):114-20.
28. Marignani M, Delle Fave G, Mecarocci S, Bordi C, Angeletti S, D'ambra G, Aprile MR, Corleto VD, Monarca B, Annibale B. High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia: a prospective screening study. The American journal of gastroenterology. 1999;94(3):766-72.
29. Corsonello A, Lattanzio F, Bustacchini S, Garasto S, Cozza A, Schepisi R, Lenci F, Luciani F, Maggio MG, Ticinesi A, Butto V. Adverse events of proton pump inhibitors: potential mechanisms. Current drug metabolism. 2018;19(2):142-54.
30. Den Elzen WP, Groeneveld Y, De Ruijter W, Souverijn JH, Le Cessie S, Assendelft WJ, Gussekloo J. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Alimentary pharmacology & therapeutics. 2008 Mar;27(6):491-7.
31. Carabotti M, Annibale B, Lahner E. Common pitfalls in the management of patients with micronutrient deficiency: Keep in mind the stomach. Nutrients. 2021;13(1):208.
32. Fihn SD, Francis J, Clancy C, Nielson C, Nelson K, Rumsfeld J, Cullen T, Bates J, Graham GL. Insights from advanced analytics at the Veterans Health Administration. Health affairs. 2014;33(7):1203-11.